The Use of Hepatitis B Virus Vaccine

Publisher Website
Google Scholar
Abstract
An inactivated subunit hepatitis B virus (HBV) vaccine was licensed in the United States in November 1981, and marketing began in June 1982. Before this vaccine was available, prevention of HBV infections depended mainly on environmental measures and on administration of immunoglobulins after exposure.1 These control measures were only variably effective. The advent of an effective vaccine2 , 3 is an important step toward the eventual control of hepatitis B in this country. However, as programs for its use begin to develop, epidemiologic and economic factors, as well as questions about its long-term safety, need to be examined and placed in perspective. . . .

This publication has 7 references indexed in Scilit: